Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
188.83B
Market cap188.83B
Price-Earnings ratio
10.18
Price-Earnings ratio10.18
Dividend yield
2.95%
Dividend yield2.95%
Average volume
9.25M
Average volume9.25M
High today
$43.16
High today$43.16
Low today
$41.77
Low today$41.77
Open price
$41.97
Open price$41.97
Volume
7.07M
Volume7.07M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

Benzinga 25m
EMA Committee Endorses Novo Nordisk's Hemophilia A Therapy

Novo Nordisk A/S (NYSE:NVO) stock is trading higher on Thursday after the Danish drug maker achieved major advances across its therapeutic pipeline after securi...

EMA Committee Endorses Novo Nordisk's Hemophilia A Therapy
Seeking Alpha 2h
Novo hemophilia therapy granted EU recommendation

Novo Nordisk (NVO) (NONOF) on Thursday announced that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed Frehemgo, an injec...

Novo hemophilia therapy granted EU recommendation
TipRanks 3h
Novo Nordisk reports CHMP adopts positive opinion on MAA for Frehemgo

Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommendin...

More NVO News

TipRanks 4h
Novo Nordisk: Market Perform and $47 Price Target Maintained Amid Obesity Strength and Competitive Risks

Novo Nordisk, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Evan Seigerman from BMO Capital maintained a Hold rating on t...

Nasdaq 1d
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?

Key Points Novo Nordisk has lost its lead in the weight loss market. The company could face even more competition going forward. However, its deep pipeline s...

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?
Benzinga 1d
Novo Nordisk, Anthropic Team Up For AI Drug Research

Novo Nordisk A/S (NYSE:NVO) announced a collaboration with Anthropic that it says will help accelerate the development of new medicines. The companies will joi...

Novo Nordisk, Anthropic Team Up For AI Drug Research
TipRanks 1d
Novo Partners with Anthropic on AI Drug Discoveries

Danish pharmaceutical giant Novo (NVO) is partnering with startup Anthropic to advance drug discoveries using artificial intelligence (AI) technologies. In a st...

The Wall Street Journal 1d
Novo Partners With Anthropic to Speed Up Drug Discovery Using Claude

Novo Nordisk and Anthropic are teaming up to deploy the Claude artificial-intelligence model. Chris Ratcliffe / Bloomberg News Novo Nordisk NOVO.B 0.54 %increa...

Novo Partners With Anthropic to Speed Up Drug Discovery Using Claude
TipRanks 1d
Novo Nordisk announces collaboration with Anthropic

The company states: “Novo Nordisk (NVO) and Anthropic announced a collaboration that will help Novo accelerate the development of new medicines and advance AI-d...

Simply Wall St 1d
Ascendis Pharma Reclaims Global TransCon Rights For Obesity And Heart Disease

Ascendis Pharma (NasdaqGS:ASND) has regained global rights to its TransCon technology in metabolic and cardiovascular diseases after ending its collaboration wi...

Ascendis Pharma Reclaims Global TransCon Rights For Obesity And Heart Disease

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.